• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ARC
Click for more information
0.00% 11.0¢

ARC FUNDS LIMITED - News & Media

Market Cap $4.304M  ! watchlist Created with Sketch. Add to my watchlist
Financial Services Asset Management

ARC Funds Limited is an Australia-based investment management company. The Company is... ARC Funds Limited is an Australia-based investment management company. The Company is developing multi-affiliate boutique funds management platform. It invests in and support the emerging funds management in Australia. The Company provides its managers, directly or via third parties, with licensing, structuring, trustee/RE, administration, custody, insurance, marketing and investor introductions and distribution.More

No News & Media currently available.

(20min delay)
Last
11.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $4.304M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 9818 9.9¢
 

Sellers (Offers)

Price($) Vol. No.
11.0¢ 7789 2
View Market Depth
Last trade - 12.22pm 28/06/2024 (20 minute delay) ?
ARC (ASX) Chart

Top Stories

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Sun Silver executive director Gerard O'Donovan discusses a 6,216 grams Fort Intercept at the Maverick Spring Silver Project from historical data and drill assessments.
Ava Risk Group expands US presence with A$0.7M Substation Deal Ava Risk Group (ASX:AVA) has announced that its latest generation Aura Ai-X intrusion detection technology has been selected for three electricity substations on the East Coast of the United States.
Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom Wealth Within's Dale Gillham weighs in on the shock 4% inflation read from the ABS midweek – and stocks that could survive the gloom.
Silver Mines models five new calderas close to 396Moz Bowdens deposit Silver Mines Ltd has identified multiple new caldera structures proximal to its Bowdens Silver Deposit in New South Wales.
Recce's R327 found effective against E.coli during clinical trial Recce Pharmaceuticals Ltd has found that its R327 drugs is effective in treating Escherichia coli during a Phase I/II clinical trial.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.